Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,342.00down ₹10.00 (0.74%)BSE ₹1,340.25
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,352.00.
2 Nov: open ₹1,352.00, high ₹1,364.90, low ₹1,336.70
52-week range of traded prices to 2 Nov 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,014 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.01
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.89
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 20,54,116
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 33 of 35.
Jan 2009
2 Jan · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated January 02, 2009, titled "Dr Reddy's announces the appointment of new Chief Financial Officer (CFO)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
23 Dec · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated December 23, 2008, titled "Dr. Reddy's Laboratories announce settlement of Clarinex (R) (Desloratadine) ANDA patent litigation with Schering Corporation and Sepracor Inc.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Dec · Disclosure
Dr. Reddy's Laboratories Ltd. has informed the Exchange that "Pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007, the Compensation Committee of the Board of Directors of the Company has allotted 7,000 ADRs of Rs.5 each of the Company on December 17, 2008, to US Employee of the Company who has exercised his ADR Stock Options."4 Dec · Allotment of shares/ others
Dr. Reddy's Laboratories Ltd. has informed the Exchange that "Pursuant to Dr. Reddy's employees stock Option Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has approved the grant of 20,000 stock options at fair market value on December 02, 2008 to an employee of the Company. Pursuant to Dr. Reddy's Employees Stock option Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has allotted 21,109 equity shares of Rs.5 each of the Company on December 02, 2008, to Employees who have exercised their Stock option. Pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007, the Compensation Committee of the Board of directors of the Company has allotted 300 ADR of Rs. 5 each of the Company on December 02, 2008, to US Employee of the Company who has exercised her ADR Stock Option".
Nov 2008
24 Nov · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated November 24, 2008, titled "Dr. Reddy's launches authorized generic version of Imitrex Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
23 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on October 23, 2008 have, subject to such approvals as are required, approved a Scheme of Amalgamation by which Perlecan Pharma Private Limited, a subsidiary of the Company will be amalgamated with Dr Reddy's Laboratories Limited, effective January 01, 2006.23 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 23, 2008, titled "Dr. Reddy's Q2 FY09 Revenue at Rs. 16,151 million, EBITDA at Rs. 2,746 million, PAT at Rs. 1,212 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Oct · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 200168 lacs for half year ending on 30-SEP-2008 against Rs. 157810 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 30105 lacs for the half year ending on 30-SEP-2008 against Rs. 27069 lacs for the half year ending on 30-SEP-2007.23 Oct · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 305720 lacs for half year ending on 30-SEP-2008 against Rs. 244844 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 17860 lacs for the half year ending on 30-SEP-2008 against Rs. 29741 lacs for the half year ending on 30-SEP-2007.23 Oct · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 92243 lacs for quarter ending on 30-SEP-2008 against Rs. 85040 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 9101 lacs for the quarter ending on 30-SEP-2008 against Rs. 12500 lacs for the quarter ending on 30-SEP-2007.23 Oct · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 157594 lacs for quarter ending on 30-SEP-2008 against Rs. 125570 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 8664 lacs for the quarter ending on 30-SEP-2008 against Rs. 11047 lacs for the quarter ending on 30-SEP-2007.14 Oct · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated October 14, 2008, titled "Dr. Reddy's wholly-owned subsidiary Promius Pharma launches EPICERAM (R) skin barrier emulsion ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Board meeting
To consider the Un-Audited financial results for the quarter and half year ended September 30, 2008. Further, the Board will consider a Scheme of Amalgamation in terms of which Perlecan Pharma Private Limited, a wholly owned subsidiary of the Company will be amalgamated with the Company.1 Oct · Disclosure of shareholding
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992 and further to the intimation received from Mr. Anupam Puri, Independent Director on the Board of the Company, we hereby intimate you that Ms. Rajika Puri, wife of Mr. Anupam Puri, has made a sale of 4000 ADRs of the Company on September 26, 2008".
Sep 2008
25 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 25, 2008, titled "Dr Reddy's enters the respiratory inhalers market in India with the launch of 'Combihale' and 'Redihaler' Forays into inhalation asthama market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Sep · Allotment
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007, the Compensation Committee of the Board of Directors of the Company has allotted 21,800 ADRs of Rs.5 each of the Company on September 23, 2008, to US Employees of the Company who have exercised their ADR Stock Options.18 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 18, 2008, titled " Dr. Reddy's formally announces its US Specialty Business, Promius Pharma, LLC". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Sep · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated September 04, 2008, titled "Dr Reddy's announces partnership with Cosmederm Technologies for Indian distribution of proprietary skin care products". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
27 Aug · Allotment of Equity Shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "Pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has allotted 65,575 equity shares of Rs.5 each of the Company on August 27, 2008, to Directors / Employees who have exercised their Stock Options".8 Aug · Updates
Dr. Reddy'S Laboratories Ltd. had informed the Exchange regarding outcome of the Annual General Meeting of the Company held on July 22, 2008. The Company has now informed the Exchange with reference to Item 8 of the outcome of the Annual General Meeting of the Company that, the proposed issue of 84,06,782 share warrants resulting into equity shares of Rs.5/- each at a later date of preferential basis in terms of Section 81 (1A) of the Companies Act, 1856 to Dr. Reddy's Holdings Private Limited, as approved at the Annual General Meeting of the Company held on July 22, 2008 stands cancelled / withdrawn as the issue / allotment has not taken place in terms of Chapter XIII-Clause 13.1.2.3(a) and Clause 13.4.1 of SEBI (Disclosure& Investor Protection) Guidelines, 2000. Pursuant to this, the Company has withdraw its application made to the stock exchanges earlier, for in-principle approval sought in respect of the above shares.
Jul 2008
30 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 30, 2008, titled "Dr. Reddy's Laboratories Limited invests in Perlecan Pharma Private Limited by acquiring shares of Joint Venture Partners". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jul · Meeting
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding the outcome of Annual General Meeting of the Company held on July 22, 2008.The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jul · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 148126 lacs for quarter ending on 30-JUN-2008 against Rs. 118809 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 9197 lacs for the quarter ending on 30-JUN-2008 against Rs. 18723 lacs for the quarter ending on 30-JUN-2007.21 Jul · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 107925 lacs for quarter ending on 30-JUN-2008 against Rs. 72770 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 21005 lacs for the quarter ending on 30-JUN-2008 against Rs. 14569 lacs for the quarter ending on 30-JUN-2007.21 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 21, 2008, titled "Dr. Reddy'S Q1 FY09 Revenue at Rs.15,038 million; EBITDA at Rs.2,710 million, PAT at Rs. 1,346 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 18, 2008, titled "Dr. Reddy'S Annual Report on Form 20-F for the year ended March 31, 2008 available on the Company's website". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jul · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated July 08, 2008, titled "Dr Reddy's signs global distribution agreement with Albemarle Corporation for Ibuprofen API". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Jul · Dividend
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the dividend, which may be declared at the Annual General Meeting scheduled to be held on July 22, 2008, shall be paid to the shareholders on or after July 29, 2008.3 Jul · Board meeting
Meeting on 21 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”2 Jul · Allotment
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007, the Compensation Committee of the Board of Directors of the Company has allotted 15,970 ADRs of Rs.5 each of the Company on July 02, 2008, to US Employees of the Company who have exercised their ADR Stock Options.
Jun 2008
17 Jun · Allotment of Equity Shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has allotted 93,297 equity shares of Rs.5 each of the Company on June 17, 2008, to Directors/Employees who have exercised their Stock Options.16 Jun · Meeting
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the register of members and share transfer books of the Company would remain closed from July 08, 2008 to July 12, 2008 (both days inclusive) for the purpose of payment of Dividend for the year 2007-08. The said payment of dividend is subject to the approval of Shareholders of the Company at the ensuing Annual General Meeting (AGM) scheduled to be held on July 22, 2008.
May 2008
29 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 29, 2008, titled "Dr Reddy's launches 'Atocor - R' - combination of Atorvastatin and Ramipril in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 22, 2008, titled "Dr Reddy's launches 'Omez Insta' - Immediate Release Omeprazole in sachets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 May · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 98887 lacs for quarter ending on 31-MAR-2008 against Rs. 105933 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 16226 lacs for the quarter ending on 31-MAR-2008 against Rs. 26890 lacs for the quarter ending on 31-MAR-2007.20 May · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 333066 lacs for year ending on 31-MAR-2008 against Rs. 375010 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 47522 lacs for the year ending on 31-MAR-2008 against Rs. 117686 lacs for the year ending on 31-MAR-2007.20 May · Board meeting
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on May 20, 2008: 1) Mr. P.N. Devarjan ceased to be the Director of the Company effective as on date. 2) The Compensation committee approved the grant of 407,220 stock options at par value to the employees of the Company. 3) The Board of Directors approved grant of 18,000 stock options at par value to the Independent Directors of the Company. 4) The Board of Directors based on the recommendation of the Compensation Committee proposed for an amendment in the existing schemes of stock options subjects to the shareholders approval. 5) The Board of Directors approved the appointment of Mr. V. S. Suresh as Company Secretary in place of Mr. V. Viswanath, who moved Director, Finance in BFROW Business Operations.20 May · Dividend
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on May 20, 2008 have recommended a final dividend of 75% i.e. Rs. 3.75 per share of the face value of Rs. 5 subject to the shareholders approval.20 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 20, 2008, titled "Dr. Reddy's FY08 Revenue at Rs.50,006 million; EBITDA at Rs.9,736 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 May · Results
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 491417 lacs for year ending on 31-MAR-2008 against Rs. 643463 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 43813 lacs for the year ending on 31-MAR-2008 against Rs. 96589 lacs for the year ending on 31-MAR-2007.5 May · Allotment of shares/ others
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has allotted 2,870 equity shares of Rs.5 each of the Company on May 03, 2008, to an Employees who has exercised his Stock Options. Further, Pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007, the Compensation Committee of the Board of Directors of the Company has allotted 17,604 ADRs of Rs.5 each of the Company on May 03, 2008, to US Employees of the Company who have exercised their ADR Stock Options.5 May · Board meeting
To interalia, consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2008 and recommend the payment of dividend for the financial year 2007-08.2 May · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated May 01, 2008, titled "Dr. Reddy's announces the completion of two acquisitions". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
30 Apr · Business
Dr. Reddy's Laboratories Ltd. has informed the Exchange regarding a press release dated April 30, 2008, titled "Dr. Reddy's Acquires BASF's Pharmaceutical Contract Manufacturing Business and related facility at Shreveport in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Apr · Allotment of Equity Shares
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "Pursuant to Dr. Reddy's Employees Stock Options Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has allotted 10,866 equity Shares of Rs. 5 each of the Company on April 21, 2008, to Employees who have exercised their Stock Options."8 Apr · Results
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "The Company will announce and publish the audited annual results of the Company for the year ended March 31, 2008 instead of unaudited quarterly results for the quarter ended March 31, 2008".3 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 03, 2008, titled "Dr. Reddy's acquires Jet Generici Srl. Acquisition to establish Generics business in Italy". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Apr · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated April 01, 2008, titled "Dr. Reddy's signs definitive agreement to acquire Dowpharma Small Molecules business associated with Dow's Mirfield and Cambridge, UK Sites". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
10 Mar · Business
Dr. Reddy'S Laboratories Ltd. has informed the Exchange regarding a press release dated March 10, 2008, titled "Dr. Reddy's Enters into Drug Discovery Collaboration with 7TM Pharma on Selected Drug Targets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
22 Feb · Allotment of Equity Shares
Dr. Reddy's Laboratories Ltd. has informed the Exchange that "Pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002, the Compensation Committee of the Board of Directors of the Company has allotted 37,094 equity shares of Rs.5 each of the Company on February 21, 2008, to Employees who have exercised their Stock Options".